



**FOR IMMEDIATE RELEASE**  
**PRESS RELEASE**  
March 7, 2007

**ANGIOTECH APPOINTS VICTOR DIAZ AS SENIOR VICE PRESIDENT,  
GLOBAL MANUFACTURING & SUPPLY CHAIN MANAGEMENT**

VANCOUVER, BC, March 7, 2007 – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the appointment of Victor Diaz as Senior Vice President, Global Manufacturing & Supply Chain Management.

“With his significant accomplishments in manufacturing and supply chain operations in health care and the medical device industries, we are pleased to welcome Victor to Angiotech’s senior management team,” said Dr. William Hunter, President and CEO of Angiotech.

Mr. Diaz has over 20 years experience in the health care, medical device, and medical instruments industries. He brings to Angiotech a solid background in global manufacturing, Six Sigma, procurement, distribution, supply chain, lean manufacturing, inventory management, ISO and FDA regulations and compliance.

“As we anticipate more growth in the future, we believe that Victor will lend his experience to align Angiotech’s people and manufacturing resources, build out our supply chain strategy, develop best practices across all of our facilities, and increase manufacturing and operational productivity,” added Dr. Hunter.

Prior to joining Angiotech, Mr. Diaz was Vice President, Global Operations at Teleflex Medical, the medical device and instrument manufacturing division of Teleflex Corporation. During his career at Teleflex, Mr. Diaz led a staff of 4,200 people and was responsible for the global manufacturing, procurement, distribution and complete supply chain with 25 plants and 23 distribution centers in 10 countries in Europe, Asia, Latin America and the U.S. Mr. Diaz also spent three years at Tyco Healthcare Respiratory where he was Vice President of Manufacturing, responsible for 11 manufacturing facilities in 5 countries in Europe, Mexico, and the U.S. Prior to joining Tyco Respiratory, Mr. Diaz was Vice President of Manufacturing for Kendall Healthcare, a subsidiary of Tyco Healthcare that manufactured disposable medical products, where he was responsible for 4,000 employees at FDA compliant ISO and EN certified plants in Europe, Mexico, Venezuela, Malaysia, Thailand and the U.S.

**Note on Forward Looking Statements:**

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words “believes,” “may,” “plans,” “will,” “estimate,” “continue,” “anticipates,” “intends,” “expects” and similar expressions, constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and constitute “forward-looking information” within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the “safe harbor” provisions of applicable securities legislation. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following; general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and any other factors that

may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include; poor performance of the product in the clinical setting; adverse events related to the use of the product; improper estimation of the size of the wound closure market in the U.S.; adverse results or unexpected delays in clinical development processes; our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; our ability to continue to integrate into our business the operations of American Medical Instruments Holdings, Inc. and our ability to achieve the operational and other synergies and the other commercial or financial benefits expected as a result of that acquisition; and any other factors referenced in our annual information form and other filings with the applicable Canadian securities regulatory authorities or the SEC.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this prospectus to reflect future results, events or developments.

## **About Angiotech**

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with 17 facilities in 6 countries and over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at [www.angiotech.com](http://www.angiotech.com).

## **FOR ADDITIONAL INFORMATION:**

Janet Craig  
VP, Investor Relations and Corporate Communications  
Angiotech Pharmaceuticals, Inc.  
(604) 221-6933  
[jcraig@angio.com](mailto:jcraig@angio.com)

Jodi Regts  
Manager, Investor Relations and Corporate Communications  
Angiotech Pharmaceuticals, Inc.  
(604) 221-7930  
[jregts@angio.com](mailto:jregts@angio.com)